Better Predictive Modelling for Better Drug Development

Predictive modelling in drug development promises to reduce uncertainty before expensive experiments and clinical studies begin. But better algorithms alone don’t deliver reliable predictions.

The next advance depends on combining computational methods with biological knowledge, experimental evidence, and rigorous model evaluation. 

Image

Why Drug Response Is Hard to Predict

Drug efficacy and toxicity do not emerge from a single molecular interaction. They result from interconnected processes spanning molecules, cells, tissues, organs, and whole patients.

A drug can interact with the same target but produce different outcomes depending on cell type, biological context, disease state, and individual characteristics.

Genetic variation, age, sex, epigenetic changes, and environmental exposure can also alter drug response. 

This creates a fundamental challenge for AI and computational drug discovery. A model that performs well at one biological level may not explain what happens at another.

Models should be more capable of capturing emergent biological behaviour across multiple scales.

That means connecting:

• Molecular mechanisms with cellular responses
• Cellular activity with tissue and organ function
• Biological mechanisms with patient-level outcomes

Pharmatica puts this principle central in our own Discovery Loop, where we continuously highlight how computational prediction should better intersect with experimental research.

Combining QSP, Machine Learning, and Systems Biology in Drug Discovery

Quantitative Systems Pharmacology (QSP), systems biology, machine learning, and related modelling approaches should be treated as complementary approaches to drug discovery rather than competing technologies.

QSP provides a mechanistic framework for representing biological systems, while machine learning can identify patterns across large datasets, and statistical and mathematical approaches can describe dynamic behaviour and relationships within complex systems.

Combining these methods can produce models that are more useful than relying on one technique alone.

That really matters. Machine learning can find patterns, but biological knowledge helps explain whether those patterns make sense.

The U.S. Food and Drug Administration (FDA) increasingly recognises the role of model-informed approaches in drug development. Its MIDD guidance establishes principles for planning, evaluating, documenting, and communicating evidence generated through model-informed drug development. 

The FDA also identifies modelling and simulation as tools that can complement experimental evidence and support scientific and regulatory decision-making. 

Read Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.

Better Models Need Better Science for Predictive Modelling in Drug Development

Predictive modelling is a scientific discipline, not simply a technology problem.

Drug developers need to establish whether a model’s biological assumptions remain appropriate, whether its pathways are represented adequately, and whether its parameters are supported by relevant evidence.

Existing models can provide a useful starting point, but they should be adapted carefully rather than reused without scrutiny.

Quantitative and qualitative behaviour are vitally important as well.

A model may reproduce numerical measurements while missing an important biological feature, such as a switch between stable biological states. Model architecture therefore matters as much as parameter accuracy.

This creates a strong case for collaboration between pharmacologists, biologists, clinicians, mathematicians, and computational scientists.

Trust Actually Determines Predictive Modelling’s Value in in Drug Development

Predictive models can support hypothesis generation, sensitivity analysis, intervention prioritisation, and development decisions. They can also help researchers explore scenarios that would be difficult, expensive, or impractical to test experimentally. 

But, models should support evidence, not pretend to replace it.

Credibility depends on transparency, reproducibility, appropriate validation, and realistic expectations about what a model can answer.

This aligns with wider efforts to improve reproducible biomedical modelling. The NIH-supported Center for Reproducible Biomedical Modeling focuses on improving model publication, reuse, and reproducibility. 

This is strategically important. As models influence drug discovery and development decisions, companies need to know not only what a model predicts, but why the prediction deserves confidence.

Predictive Modelling Moves Towards The Whole System

A more integrated future for predictive modelling in drug development is needed.

The objective is not simply to create increasingly sophisticated models, but to build models that connect biological knowledge, diverse evidence, computational methods, and real-world uncertainty.

For drug discovery leaders, that changes the question from How powerful is the model? to How credible is the decision it supports?

That distinction could shape how AI, QSP, systems biology, and modelling become embedded in the Drug Discovery Loop.

At Pharmatica, we examine the technologies, scientific systems, and strategies reshaping pharmaceutical R&D, connecting emerging innovation with the decisions that determine its real-world value.

Image